|
|
 |
| |
|
|
|
Circulating MicroRNA-143 and MicroRNA-122 as Prognostic Biomarkers in Egyptian Hepatocellular Carcinoma Patients |
|
|
|
PP: 777-789 |
|
|
|
doi:10.18576/isl/130404
|
|
|
|
Author(s) |
|
|
|
Ghada M. Nasr,
Abubakr G. Basiouny,
Mohamed Y. Nasr,
Eman A. Badr,
Ali S. Nada,
Randa M. Seddik,
Samir A. Elmasry,
Hadia A. Heikal,
|
|
|
|
Abstract |
|
|
| In this study, we investigate the expression profile of miRNA-122 and miRNA-143 in HCC patients and assess their clinical utility as novel HCC prognostic markers as early as feasible to enhance patient prognosis. This prospective case-control study involved 150 Egyptian participants, 50 of whom had HCC, 50 had liver cirrhosis (LC), and 50 were healthy. The microRNAs (miR-122 and miR-143) were quantified using reverse transcription real-time PCR. While miR- 122 expression levels were downregulated compared to controls and LC groups; miR-143 expression levels were upregulated in HCC patients. MiRNAs (miR-122 and miR-143) had a strong diagnostic potential for HCC. With a sensitivity of 82% and specificity of 100%, combined measurement of miRNA 143+ miRNA 122 was statistically significant in differentiating between HCC and LC patients at AUC 0.89. By univariate analysis, miR-143 showed its value as a significant predictor of mortality (P<0.001). Studied microRNAs (miR-122 and miR-143) may be used as early, non- invasive indicators for both diagnosis and prognosis of HCC.
|
|
|
|
|
|
|
|
